Data from Phase 2 Study of Tazemetostat for Epithelioid Sarcoma to be Presented at ASCO
Epizyme, Inc announced that multiple abstracts have been accepted for presentation during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program held May 29-31, 2020.
“We are pleased to participate in ASCO’s virtual program, reporting the pooled data from the two Phase 2 study cohorts of tazemetostat for epithelioid sarcoma, which supported the approval of TAZVERIK™ in January, as well as a presentation of the trial design for our ongoing confirmatory trial in epithelioid sarcoma,” said Dr. Shefali Agarwal in a press release. “We will also report the final data from our study of tazemetostat as a monotherapy for mesothelioma, originally presented at ASCO 2018, and early data from the Phase 1b portion of our trial of tazemetostat in pediatric patients with INI1-negative tumors. As we look ahead, 2020 is an important year for the commercialization of TAZVERIK, as well as advancing our tazemetostat clinical program in multiple additional cancer indications and combinations.”
Below is some of the abstract details.
Title: Efficacy, safety, and immune priming effect of tazemetostat in patients with epithelioid sarcoma
Authors: Mrinal M. Gounder, Silvia Stacchiotti, Patrick Schoffski, Gregory M. Cote, Victor M. Villalobos, Thierry M. Jahan, Tom Wei-Wu Chen, Ravin Ratan, Abha A. Gupta, Palma Dileo, Mark Agulnik, Antoine Italiano, Steven Attia, Olivier Mir, Joseph G. Pressey, Laura Sierra, Trupti Lingaraj, Jay Yang, Shefali Agarwal, Robin L. Jones
Title: A phase Ib/III randomized, double-blind, placebo-controlled study of tazemetostat plus doxorubicin as frontline therapy for patients with advanced epithelioid sarcoma
Authors: Shiraj Sen, Meredith A. McKean, Laura Sierra, Jessica Ainscough, Jay Yang, Anthony Hamlett, Tom Zimmerman, Melinda Merchant, Sant P. Chawla
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809